SCHEMBL3359926

SCHEMBL3359926

Nc1n[nH]c2ccc(-c3cccc4[nH]ccc34)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.59
JAK3 P52333 2/20 0.59
JAK1 P23458 1/20 0.59
TYK2 P29597 1/20 0.59
PIK3CD O00329 3/20 0.56
PIK3CB P42338 2/20 0.56
CHEK1 O14757 1/20 0.53
ASH1L Q9NR48 1/20 0.51
PIK3CG P48736 1/20 0.51
KDR P35968 3/20 0.46
KIT P10721 1/20 0.46
FLT3 P36888 1/20 0.46
CSNK2A1 P68400 3/20 0.45
AURKA O14965 2/20 0.45
CDK1 P06493 2/20 0.45
FGFR1 P11362 2/20 0.45
PRKACA P17612 2/20 0.45
CDK2 P24941 2/20 0.45
MARK3 P27448 2/20 0.45
AKT1 P31749 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14020099 0.78 CCNK (0.58) JAK2JAK3JAK1TYK2CHEK1
SCHEMBL31420118 0.78 CCNK (0.58) JAK2JAK3JAK1TYK2CHEK1
SCHEMBL29968270 0.76 KDR (0.62) JAK2JAK3TYK2KDRKIT
SCHEMBL419502 0.76 KDR (0.62) JAK2JAK3TYK2KDRKIT
SCHEMBL10213928 0.76 JAK2 (0.61) JAK2JAK3JAK1TYK2KDR
SCHEMBL10213929 0.76 JAK2 (0.81) JAK2JAK3JAK1TYK2KDR
SCHEMBL5514612 0.76 PDPK1 (0.61) JAK2JAK3JAK1TYK2CHEK1
SCHEMBL7088454 0.75 PIK3CD (0.62) PIK3CDPIK3CBCHEK1ASH1LPIK3CG
SCHEMBL982028 0.75 ASH1L (0.63) PIK3CDPIK3CBCHEK1ASH1LPIK3CG
SCHEMBL1251611 0.75 PIK3CD (0.47) JAK2PIK3CDPIK3CBCHEK1ASH1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638941-B1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LAB (US) 2010-06-02 EP disclosed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 JAK2 127/4885JAK3 582/4885JAK1 586/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 JAK2 127/4885JAK3 582/4885JAK1 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.